Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox 4 like 26 (DUX4L26) is annotated as a **pseudogene**, implying it does not encode a functional protein and does not directly contribute to known cellular functions, therapeutic targeting, or disease processes[4]. Unlike DUX4, which is a functional transcription factor implicated in embryogenesis and certain diseases[1][5], DUX4L26 is not described in scientific literature as encoding a protein, nor does it act as a therapeutic target or have documented biological roles. There is no evidence for DUX4L26 involvement in pathology, molecular interactions, or drug targeting. The presence of "DUX4L26" likely arises from its sequence similarity to DUX4 within the genome, leading to its designation as "like 26" among several DUX4-related pseudogenes. It does not possess the functional domains or biological activities ascribed to DUX4.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double homeobox 4 like 26 (DUX4L26).